While it is a truth universally acknowledged that patients with malignancy are at substantially high risk for venous thromboembolism (VTE) as compared with the general population, the incidence of VTE varies significantly between subgroups of cancer patients, and even in the same patient over time. Broadly speaking, the risk in the general cancer population has been estimated to be 13 per 1,000 personyears (95% confidence interval [CI], [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 
While it is a truth universally acknowledged that patients with malignancy are at substantially high risk for venous thromboembolism (VTE) as compared with the general population, the incidence of VTE varies significantly between subgroups of cancer patients, and even in the same patient over time. Broadly speaking, the risk in the general cancer population has been estimated to be 13 per 1,000 personyears (95% confidence interval [CI], 7-23) in a recent systematic review.
1 This general estimate, however, does not accurately reflect the prevalence of clinical events observed in cancer patients on active treatment. For instance, in a report of 932 cancer patients receiving cisplatin-based therapy at a large cancer center, 169 (18.1%) experienced a thromboembolic event during treatment or within 4 weeks of the last dose. 2 Similarly, the rate of VTE in the placebo arm of a trial of thromboprophylaxis in patients with advanced pancreas cancer was 23% over 100 days. 3 Thus, the risk can be unacceptably high in certain well-defined subgroups and during certain settings. Because of this wide variation in risk, a recent update by the American Society of Clinical Oncology (ASCO) VTE Guidelines Panel recommends that patients with cancer be assessed for VTE risk at the time of chemotherapy initiation and periodically thereafter (recommendation 6.1).
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This review will discuss the known risk factors associated with VTE in malignancy, available and candidate predictive biomarkers, and the application of a risk score to assess level of risk in this setting.
Risk Factors
The risk of VTE varies depending upon individual patientspecific, disease-specific, and treatment-specific clinical risk factors (►Table 1). The patient-specific risk factors include age, race/ethnicity, presence of comorbidities, and history of VTE. Older age and African American ethnicity increase the risk of VTE in cancer patients. 5 Cancer patients with a history of VTE are six to seven times more likely to develop new VTE than those without a history of VTE. 6 Comorbidities such as congestive heart failure and chronic obstructive pulmonary disease may further increase the risk of VTE in cancer patients. A recent article suggests that presence of varicose veins is associated with an increased risk of cancer-associated VTE.
extension of disease. The primary site of cancer appears to be the most important disease-specific risk factor. Cancer of the brain, pancreas, stomach, liver, lungs, and kidneys consistently display the highest association with VTE events (as reviewed by Khorana et al 8 ). In addition, emerging data suggest that VTE rates associated with hematologic malignancies, particularly myeloma, lymphomas, and leukemias appear to be similar to those seen with several solid tumors. 9, 10 Rates of VTE may differ even between different histological types of disease involving the same organ, with adenocarcinomas being typically associated with higher VTE risk than squamous cell carcinomas. 11 The incidence of VTE in patients with non-small cell lung cancer is twice as high as that in patients with small cell lung cancer. 12 Other differences in histology can also alter risk of VTE; in a recent article, patients with high-grade tumors had higher risk of VTE compared with low-grade tumors.
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The risk of VTE appears to be highest early in the course of the underlying malignant disease. A large population-based case-control study showed that the risk of VTE was highest within the first 3 months following the diagnosis of a malignancy, with an adjusted odds ratio (OR) of 53.5 (95% CI, 8.6-334.3) compared with controls without malignancy.
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The burden of malignancy is importantly associated with risk. Data from the MEGA (Multiple Environmental and Genetic Assessment) case-control study revealed that cancer patients with distant metastases had a 20-and a 58-fold increased risk of VTE compared with those with cancer without distant metastases and without malignancy, respectively. 10 Even regional disease can alter risk. In a report from the Vienna group, the cumulative probability of VTE after 6 months in patients with local, regional, and distant stage cancer was 2.1, 6.5, and 6.0%, respectively (p ¼ 0.002). The authors concluded that PICCs are associated with a higher risk of DVT than CVCs, especially in patients who are critically ill or with malignancy. IVC filters, although commonly used to prevent pulmonary embolism in patients with cancer with contraindications to anticoagulation are in fact known to increase rates of DVT. A rate of recurrent VTE of 32% following IVC filter placement has been reported in cancer patients.
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The use of systemic chemotherapy seems to increase the risk of VTE beyond what is expected from the disease itself, and is associated with up to 6-fold increased risk of VTE compared with the general population. 19 The risk can vary 
Risk Assessment Tools
As the long list of known risk factors and biomarkers associated with VTE in malignancy indicates, the etiology of cancerassociated VTE is multifactorial. Multiple large randomized trials have attempted to identify patients at high risk for VTE based on one or two risk factors such as type of cancer and use of chemotherapy. 35, 36 However, event rates in such studies have been quite low indicating that a high-risk population was not selected. Based on these data, the 2013 ASCO VTE Guidelines Panel recommends against the use of single risk factors or biomarkers to identify high-risk patients. 4 Rather, the panel recommends the use of a risk score that incorporates multiple variables to identify high-risk patients (►Table 3). The risk score for cancer-associated VTE was originally derived from a development cohort of 2,701 patients and then validated in an independent cohort of 1,365 patients from a prospective registry. 37 Subsequently, the risk score was externally validated prospectively by the Vienna CATS (Cancer and Thrombosis Study) research group in 819 cancer patients. 38 The 6-month cumulative probabilities of developing VTE in the Vienna cohort were 1.5% (score of 0), 3.8% (score of 1), 9.4% (score of 2), and 17.7% (score 3). Multiple other cohort studies have further validated this score, although rates vary between studies based on heterogeneous populations and follow-up periods. 39 In addition to the ASCO guidelines, the risk score has also been endorsed by the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO)guidelines panels.
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Expansions of the risk score have been proposed but not yet validated; one such expansion by the Vienna group incorporates additional biomarkers including D-dimer and soluble P-selectin. 38 In the expanded Vienna risk model, the cumulative VTE probability after 6 months in patients with the highest score ( 5) 
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The algorithm is based on expert consensus and awaits validation.
Potential Applications of the Risk Score
The development of a validated formal risk assessment approach is an important advance for the field. There are at least three potential clinical applications of the risk score. First, cancer patients are woefully unaware of the risk of VTE. 43 Conducting a formal risk assessment provides an opportunity to educate patients about the warning signs and symptoms of VTE. Indeed, the new ASCO guidelines recommend that oncologists educate patients regarding VTE, particularly in high-risk settings (recommendation 6.2).
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Second, one small study suggests that screening high-risk patients as identified by the risk score can lead to diagnosis of occult VTE; in this cohort, 11% of patients had undiagnosed VTE at baseline (before starting chemotherapy). These data need confirmation, however, before clinical screening can be recommended. Finally, and perhaps most promisingly, the risk score appears to be predictive of benefit from thromboprophylaxis. When risk assessment was applied to the study population of a randomized trial of outpatient prophylaxis using nadroparin, the number need to treat to prevent one thromboembolic event fell from 50 for the full population to 15 for high-risk patients (score 3). 44 Similarly, when applied to the study population of a large randomized trial of semuloparin for outpatient thromboprophylaxis, risk reduction was greater in high-risk patients (5.4% in the placebo arm vs. 
Conclusions
The past decade has led to the identification of several novel clinical risk factors as well as biomarkers predictive of risk of cancer-associated VTE. Unfortunately, the prevalence of VTE has risen during this time as well. The development of a validated formal risk assessment score is an important step forward in the field. New guidelines recommend that clinicians conduct risk assessment in all cancer patients initiating chemotherapy and periodically thereafter. Potential applications of risk assessment include patient education, screening, and selection of patients for outpatient thromboprophylaxis.
Ongoing studies are evaluating new biomarker and -omicsbased approaches to risk stratification. Building on existing knowledge, these approaches will further lead to targeted thromboprophylaxis and treatment that will reduce the burden of thrombosis and its consequences for patients with malignancy. 
